title: Interleukin 10 inhibits growth and granulocyte/macrophage colony-stimulating factor production in chronic myelomonocytic leukemia cells.
abstract: Autonomous release of hematopoietic growth factors may play a crucial role in the pathogenesis of certain hematological malignancies. Because of its cytokine synthesis-inhibiting action, interleukin 10 (IL-10) could be a potentially useful molecule to affect leukemic cell growth in such disorders. Chronic myelomonocytic leukemia (CMML) cells spontaneously form myeloid colonies (colony-forming units-granulocyte/macrophage) in methylcellulose, suggesting an autocrine growth factor-mediated mechanism. We studied the effect of recombinant human IL-10 (rhIL-10) on the in vitro growth of mononuclear cells obtained from peripheral blood or bone marrow of patients with CMML. IL-10 specifically binding to leukemic cells had a profound and dose-dependent inhibitory effect on autonomous in vitro growth of CMML cells. IL-10 significantly inhibited the spontaneous growth of myeloid colonies in methylcellulose in 10/11 patients, and autonomous CMML cell growth in suspension in 5/5 patients tested. Spontaneous colony growth from CMML cells was also markedly reduced by addition of antigranulocyte/macrophage colony-stimulating factor (GM-CSF) antibodies, but not by addition of antibodies against G-CSF, IL-3, or IL-6, IL-10-induced suppression of CMML cell growth was reversed by the addition of exogenous GM-CSF and correlated with a substantial decrease in GM-CSF production by leukemic cells, both at the mRNA and protein levels. Our data indicate that IL-10 profoundly inhibits the autonomous growth of CMML cells in vitro most likely through suppression of endogenous GM-CSF release. This observation suggests therapeutic evaluation of rhIL-10 in patients with CMML.
authors.affiliation: Division of Hematology-Internal Medicine I, University of Vienna, Austria.
authors.forename: K
authors.initials: K
authors.lastname: Geissler
authors.forename: L
authors.initials: L
authors.lastname: Ohler
authors.forename: M
authors.initials: M
authors.lastname: Födinger
authors.forename: I
authors.initials: I
authors.lastname: Virgolini
authors.forename: M
authors.initials: M
authors.lastname: Leimer
authors.forename: E
authors.initials: E
authors.lastname: Kabrna
authors.forename: M
authors.initials: M
authors.lastname: Kollars
authors.forename: S
authors.initials: S
authors.lastname: Skoupy
authors.forename: B
authors.initials: B
authors.lastname: Bohle
authors.forename: M
authors.initials: M
authors.lastname: Rogy
authors.forename: K
authors.initials: K
authors.lastname: Lechner
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002455:Cell Division / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000096:biosynthesis* / Q000235:genetics; D006131:Growth Inhibitors / Q000494:pharmacology*; D006801:Humans; D016753:Interleukin-10 / Q000494:pharmacology*; D015477:Leukemia, Myelomonocytic, Chronic / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011485:Protein Binding; D012333:RNA, Messenger / Q000032:analysis; D012334:RNA, Neoplasm / Q000032:analysis; D011994:Recombinant Proteins / Q000494:pharmacology; D013234:Stem Cells; D014407:Tumor Cells, Cultured
chemical_list: D006131:Growth Inhibitors; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D011994:Recombinant Proteins; D016753:Interleukin-10; D016178:Granulocyte-Macrophage Colony-Stimulating Factor